Other News To Note
Friday, April 27, 2012
Clinuvel Pharmaceuticals Ltd., of Melbourne, Australia, said two leading health insurers in Switzerland agreed to fully reimburse the cost of Scenesse (afamelanotide 16-mg implant) for erythropoietic protoporphyria, a rare disease characterized by severe phototoxicity.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.